^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    S95027

    i
    Other names: Sym015, Hu9006/Hu9338, S95027
    Company:
    Servier
    Drug class:
    c-MET inhibitor
    Related drugs:
    over3years
    Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
    P1a, N=57, Completed, Symphogen A/S | Active, not recruiting --> Completed
    Clinical • Trial completion
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    |
    S95027
    4years
    [VIRTUAL] Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14∆). (ASCO 2020)
    P1a | "Sym015 was well-tolerated at the RP2D with a response rate similar to MET TKI in MET-treatment naïve METAmp/Ex14Δ NSCLC and seems to delay disease progression in MET TKI pretreated NSCLC pts. Combination with MET TKI to delay or prevent resistance should be further explored. Research Funding: Symphogen A/S"
    Clinical
    |
    MET amplification • MET exon 14 mutation • MET exon 14 deletion
    |
    Guardant360® CDx
    |
    S95027
    over4years
    Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
    P1a, N=72, Active, not recruiting, Symphogen A/S | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2019 --> Oct 2020
    Clinical • Enrollment closed • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    |
    S95027